Cryopyrin-associated Periodic Syndromes (CAPS) is a rare group of auto-inflammatory and known autosomal dominant disorder that is believed to be caused due to a mutation on the exon 3 of the NLRP3 gene, which codes for Cryopyrin protein.
&nbsp;
CAPS comprises a group of three disorders, varying with their severity and the organs they tend to affect upon the onset, namely Neonatal Onset Multisystem Inflammatory Disease (NOMID), also known as Chronic Inflammatory Neurological Cutaneous Articular Syndrome (CINCA), Familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).
&nbsp;
<a href="https://www.delveinsight.com/report-store/cryopyrin-associated-periodic-syndromes-caps-epidemiology-forecast">Cryopyrin-associated Periodic Syndromes Epidemiological Segmentation</a>
The Epidemiological Segmentation of Cryopyrin-associated Periodic Syndromes in the United States from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Prevalent Cases</li>
<li>Total Diagnosed Prevalent Cases of CAPS&nbsp;</li>
<li>Age-Specific Prevalent Cases of CAPS</li>
<li>Type-specific Prevalent Cases of CAPS</li>
<li>Severity-specific Prevalent Cases of CAPS</li>
<li>Treated cases of CAPS&nbsp;</li>
</ul>
&nbsp;
Cryopyrin-associated Periodic Syndromes Epidemiology&nbsp;
<ul>
<li>The total prevalent cases of CAPS in the United States were 650 cases in 2017.&nbsp;</li>
<li>The highest number of type-specific prevalent cases were recorded for FCAS in the United States, with 293 cases in 2017.&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/cryopyrin-associated-periodic-syndromes-caps-market" target="_blank" rel="noopener noreferrer">Cryopyrin-associated Periodic Syndromes Market</a>
The overall CAPS market size in the United States in 2017 was USD 36 million.&nbsp;
&nbsp;
Cryopyrin-associated Periodic Syndromes Market Drivers
<ul>
<li>Improvement in the treatment strategies</li>
<li>Advances in Research and Development</li>
<li>Less competitive scenario</li>
</ul>
&nbsp;
Cryopyrin-associated Periodic Syndromes Market Barriers
<ul>
<li>Lack of awareness in the care providers</li>
<li>The high cost of research and low return on investment</li>
<li>The limited patient population in clinical trials</li>
</ul>
&nbsp;
<a href="https://www.delveinsight.com/report-store/cryopyrin-associated-periodic-syndrome-caps-pipeline-insight">Cryopyrin-associated Periodic Syndromes Emerging Drugs</a>
The Emerging Drugs of the Cryopyrin-associated Periodic Syndromes market are&nbsp;
<ul>
<li>ATI-450</li>
</ul>
And many others.&nbsp;
&nbsp;
Cryopyrin-associated Periodic Syndromes Marketed Therapies&nbsp;
The Marketed Therapies of the Cryopyrin-associated Periodic Syndromes market are&nbsp;
<ul>
<li>Kineret (Anakinra)</li>
<li>Ilaris (Canakinumab)</li>
<li>Arcalyst (Rilonacept)</li>
</ul>
And many others.&nbsp;
&nbsp;
Cryopyrin-associated Periodic Syndromes Key Players
The key players in the Cryopyrin-associated Periodic Syndromes market are
<ul>
<li>Aclaris Therapeutics</li>
<li>Amgen</li>
<li>Swedish Orphan Biovitrum</li>
<li>Novartis</li>
<li>Regeneron Pharmaceuticals</li>
</ul>
And many others.&nbsp;

Cryopyrin-associated Periodic Syndromes Market

Cryopyrin-associated Periodic Syndromes Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.